Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.

@article{Locatelli1994UseOR,
  title={Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.},
  author={Franco Locatelli and Marco Zecca and Paolo Pedrazzoli and Luisella Prete and Silvana Quaglini and Patrizia Comoli and Piero de Stefano and Yves Beguin and Gioacchino Robustelli della Cuna and Francesca Severi},
  journal={Bone marrow transplantation},
  year={1994},
  volume={13 4},
  pages={403-10}
}
We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) in children undergoing allogeneic or mafosfamide-purged autologous BMT for ALL or AML. rHuEPO was administered intravenously at a dose of 75 U/kg/day for 30 days after transplant. Ten rHuEPO-treated patients receiving allogeneic BMT and 10 given autologous BMT were compared with 15 allogeneic and 10 autologous historical controls. Endogenous EPO production was appropriate for the degree of anemia after… CONTINUE READING